Lv1
20 积分 2024-09-09 加入
Emerging therapeutic modalities of PARP inhibitors in breast cancer
5个月前
已完结
FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer
5个月前
已完结
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update
5个月前
已完结
The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancer
5个月前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
6个月前
已完结
Angiogenesis and immune microenvironment in triple-negative breast cancer: Targeted therapy
7个月前
已完结
PD-1/PD-L1 inhibitors combined with anti-angiogenic drugs for advanced triple-negative breast cancer: synergistic mechanisms and research progress
8个月前
已完结
Chemoimmunotherapy synergism: mechanisms and clinical applications
9个月前
已完结
Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates
9个月前
已完结
Immunotherapy in Combination with Chemotherapy for Triple-negativeBreast Cancer
9个月前
已完结
皖公网安备34019202002308
